Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $185.00 short put and a strike $175.00 long put offers a potential 18.2% return on risk over the next 31 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $185.00 by expiration. The full premium credit of $1.54 would be kept by the premium seller. The risk of $8.46 would be incurred if the stock dropped below the $175.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 59.3 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Barron's Picks And Pans: Apple, Amgen, TreeHouse Foods And More
Sat, 17 Nov 2018 21:27:52 +0000
This weekend's Barron's looks at some retailers that could be poised to thrive this holiday season. Other featured articles offer where to find bargains in energy stocks and selections from a noted stock …
This Biotech Stock Is a Remedy for Tougher Times
Fri, 16 Nov 2018 15:39:00 +0000
Fears about competition from biosimilars are more reflected in the biotech’s share price than its new products, legal protections, and the funds available for buybacks and dividends.
Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Fri, 16 Nov 2018 14:00:00 +0000
First and Only EU Marketing Authorization Application to Include Presence of Minimal Residual Disease Application Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual …
Migraine-Focused Biotech Has A Headache On Quarterly Losses
Wed, 14 Nov 2018 21:06:27 +0000
Biohaven Pharmaceutical slumped to a three-week low Wednesday after the biotech reported greater-than-expected third-quarter losses.
See what the IHS Markit Score report has to say about Amgen Inc.
Wed, 14 Nov 2018 13:00:39 +0000
Amgen Inc NASDAQ/NGS:AMGN
Also on Market Tamer…
Follow Us on Facebook